Although funding decisions are still taken by each of Scotland’s 14 Regional Health Boards they all now have an additional weapon in their armoury to use against Hepatitis C. For the first time there is a single pill containing two drugs which can be taken without interferon to treat adults with genotype 1 or 4 Hepatitis C (the company has some data on genotype 3 but didn’t feel it was statistically powerful enough to include in this submission).
Haemophilia Scotland made an official submission to the SMC process in support of approval and we are very please to learn we have been successful.
The next decision on a Hepatitis C therapy from the SMC will be on ombitasvir/paritaprevir ritonavir (Viekirax) and dasabuvir (Exviera). Patient organisations have until the end of the month to make submissions. Haemophilia Scotland will continue arguing for sufficient products to provide meaningful patient and clinical choice. We are also campaigning for these therapies, once approved, to be funded for people affected by the contaminated blood disaster.